Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Azacitidine Maintenance Post-AlloSCT in MDS/AML
NCT06598384Phase 2Not yet recruiting
- Start
- Sep 2024
- Primary completion
- Sep 2030
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of venetoclax in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS). Planned start Sep 2024; status: not yet recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06598384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06598384.